Inflammatix, Inc.

11 articles with Inflammatix, Inc.

• Inflammatix Appoints Amy Boyle as Chief Operating Officer

  4/15/2021

  Inflammatix , a pioneering molecular diagnostics company, announced today the appointment of experienced medical device executive Amy Boyle as Chief Operating Officer, effective April 5, 2021.

• 

  Money on the Move: March 10-16

  3/17/2021

  Life sciences money is seemingly growing on trees this year. Here's who picked a good harvest this week.

• Inflammatix Secures $102 Million in Series D Financing Led by D1 Capital Partners to Commercialize Novel Host Response Diagnostics

  3/16/2021

  Inflammatix , a pioneering molecular diagnostics company, announced today the closing of a $102 million Series D round of financing to support development and commercialization of its novel immune response diagnostics portfolio. D1 Capital Partners led the round, with participation from the company’s existing investors, including Northpond Ventures, Khosla Ventures, Think.Health, and OSF Healthcare Ventures.

• 

  Biotechs Have Busy Week of Financing Rounds

  3/16/2021

  Yesterday marked the close of three new financing rounds in the biotech space. Although none of today’s are that large, there is still plenty of money on the move. Here’s a look.

• Inflammatix Announces $7.4 Million in Additional BARDA Funding to Advance ViraBac EZ Acute Infection Test

  10/29/2020

  Second Tranche of BARDA Funding Supports Diagnostic Designed to Read Immune System and Rapidly Diagnose Acute Infection at Point of Care

• DARPA Awards Inflammatix up to $1.1 Million to Develop Diagnostic That Predicts COVID-19 Severity Risk

  9/29/2020

  New Data Shows Inflammatix Machine Learning-Based Approach of Reading Immune System is Superior to IL-6 and Other Measures in Predicting Patients at High Risk for Severe COVID-19 BURLINGAME, Calif.--( BUSINESS WIRE )-- Inflammatix , a pioneering molecular diagnostics company, announced today that the Defense Advanced Research Projects Agency (DARPA) has awarded the company up to $1.1 million for further development of a rapid diagnostic that reads

• New Inflammatix Study in Nature Communications Outlines Breakthrough in Diagnosing Acute Infections by Reading the Immune System

  3/4/2020

  Inflammatix, a pioneering molecular diagnostics company delivering precision medicine at the point of care, announced findings from a new study published today in Nature Communications that demonstrate its ability to identify patients with bacterial versus viral infections using a data-driven approach that measures the immune system response.

• Inflammatix Wins AACC's Disruptive Technology Award For Its Rapid HostDx™ Tests

  8/6/2019

   Inflammatix, a molecular diagnostics company that is reimagining diagnostics, announced today that it has received the American Association for Clinical Chemistry's (AACC) Disruptive Technology Award for its rapid HostDx™ tests, which read the immune system to improve diagnosis of acute infections and sepsis.

• Inflammatix Named a Finalist for AACC's Disruptive Technology Award For Its Rapid HostDx™ Tests

  5/16/2019

  Inflammatix announced today that it has been named a finalist for the American Association for Clinical Chemistry's (AACC) Disruptive Technology Award for its rapid HostDx™ tests, which read the immune system to improve diagnosis of acute infections and sepsis.

• Inflammatix to Present New Data at IDWeek 2018 Demonstrating Ability to Perform HostDx™ Fever Test to Rapidly Distinguish Bacterial from Viral Infections Across Multiple Laboratory Platforms

  10/4/2018

  Novel data-driven test reads the immune system response to help diagnose acute infections

• Inflammatix Announces Appointment of Oliver Liesenfeld, M.D., as CMO

  12/19/2017

  Dr. Liesenfeld, a veteran of the diagnostics industry, comes to the company from Roche Molecular Diagnostics, where he served as chief medical officer since 2012.